Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: Role of GLP-1 and GLP-1 receptor-Reference-Cited by-同舟云学术

Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: Role of GLP-1 and GLP-1 receptor

Published:2013-11 Issue:1-3 Volume:720 Page:158-165
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Abd El Motteleb Dalia M.,Elshazly Shimaa M.

Publisher

Elsevier BV

Subject

Pharmacology

Reference53 articles.

1. Oxidative stress and nitric oxide in kidney function;Araujo;Curr. Opin. Nephrol. Hypertens,2006

2. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review;Baggio;Treat. Endocrinol,2002

3. Theory and Practice of Histological Techniques;Bancroft,2002

4. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage;Baylis;J. Clin. Invest,1992

5. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers;Bergman;Clin. Ther,2006

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Macrophages communicate with mesangial cells through the CXCL12/DPP4 axis in lupus nephritis pathogenesis;Cell Death & Disease;2024-05-18

2. The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms;Current Opinion in Pharmacology;2023-04

3. Hepatoprotective effect of dipeptidyl peptidase-4 inhibitor sitagliptin against carbon tetrachloride-induced liver fibrosis in mice;Al-Azhar Assiut Medical Journal;2021-07

4. DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice;American Journal of Physiology-Renal Physiology;2021-03-01

5. DPP4/CD32b/NF-κB Circuit: A Novel Druggable Target for Inhibiting CRP-Driven Diabetic Nephropathy;Molecular Therapy;2021-01